Dermatitis News

Serum dupilumab levels showed no correlation to treatment response or adverse events in patients with atopic dermatitis during the first year of treatment, according to a study.

Patients with inflammatory skin conditions from underrepresented racial and ethnic groups, especially Black and Hispanic patients, face more health care barriers than non-Hispanic white patients, according to a cross-sectional study.

Dermavant Sciences announced positive results from its maximal usage study of Vtama cream in the treatment of atopic dermatitis for children aged as young as 2 years, according to a company press release.

The results of pooled safety data for Adbry showed positive effects in the prolonged treatment of moderate to severe atopic dermatitis, according to a study.

Upadacitinib was well tolerated with no new important safety risks among patients with moderate to severe atopic dermatitis treated for approximately 1 year, according to a study published in The Journal of Allergy & Clinical Immunology.

Eli Lilly and Company has submitted its biologics license application to the FDA for lebrikizumab, a treatment for moderate to severe atopic dermatitis, according to the company’s quarterly earnings report.

Arcutis Biotherapeutics announced the results of a nationwide survey that revealed a lack of diagnosis efficiency in adults with seborrheic dermatitis.

A 200 mg dose of abrocitinib met stringent efficacy endpoints among substantial portions of patients with moderate to severe atopic dermatitis, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

Clinics visits for itch and atopic dermatitis increased among adults aged 65 years and older during the California Camp Fire in 2018 compared with weeks without wildfire, according to a research letter published in JAMA Network Open.

A novel investigational compound derived from baby spinach leaves yielded improvements in efficacy with an attractive safety profile in adults with atopic dermatitis, according to a study.